GENFF (Genflow Biosciences) Accounts Payable: $0.87 Mil (As of Dec. 2025)


What is Genflow Biosciences Accounts Payable?

Genflow Biosciences GENFF Accounts Payable is $0.87 Mil as of Dec. 2025. The stock has 1 warning sign investors should review.

Genflow Biosciences's Accounts Payable for the quarter that ended in Dec. 2025 was $0.87 Mil.

Genflow Biosciences's quarterly Accounts Payable increased from Dec. 2024 ($0.47 Mil) to Jun. 2025 ($0.78 Mil) and increased from Jun. 2025 ($0.78 Mil) to Dec. 2025 ($0.87 Mil).

Genflow Biosciences's annual Accounts Payable declined from Dec. 2023 ($0.61 Mil) to Dec. 2024 ($0.47 Mil) but then increased from Dec. 2024 ($0.47 Mil) to Dec. 2025 ($0.87 Mil).

Genflow Biosciences Accounts Payable Related Terms

Genflow Biosciences Accounts Payable Historical Data

* Premium members only.

The historical data trend for Genflow Biosciences's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genflow Biosciences Accounts Payable Chart

Genflow Biosciences Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
0.05 0.10 0.61 0.47 0.87

Genflow Biosciences Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.61 0.56 0.47 0.78 0.87

Genflow Biosciences Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $0.87 Mil mean?
Genflow Biosciences (GENFF) has a Accounts Payable of $0.87 Mil as of Dec. 2025. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Genflow Biosciences and its competitors.
Is Genflow Biosciences' Accounts Payable too high?
Genflow Biosciences' current Accounts Payable is $0.87 Mil.
How does Genflow Biosciences' Accounts Payable compare to VRTX and REGN?
Genflow Biosciences' Accounts Payable of $0.87 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Genflow Biosciences and its competitors. Genflow Biosciences's current Accounts Payable is $0.87 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genflow Biosciences stock overvalued right now?
Genflow Biosciences (GENFF) has a current Accounts Payable of $0.87 Mil. The current Accounts Payable is $0.87 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Genflow Biosciences (GENFF), the current Accounts Payable is $0.87 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genflow Biosciences Business Description

Other Exchanges GENF:UKWQ5:Germany
Address 6 Heddon Street, London, GBR, W1B 4BT
Genflow Biosciences PLC is a preclinical biotechnology company focused on the development of biological interventions (namely gene therapies) which are aimed at tackling the effects of aging, potentially slowing or halting the aging process and so reducing the incidence of age-related diseases and thereby increasing health span. Its flagship compound, GF-1002, is based on the delivery of a variant of the SIRT6 gene and is currently in preclinical development.